Skip to content
Buy This GLP
← Research
Evidence

Malnutrition: the clinicians recorded 0.12%, the bloodwork found more

Across 19 trials, investigators logged malnutrition in 0.12% of participants. Lab screening flagged low lymphocyte counts in 2.90% — against 1.77% on placebo.

Neil Sanders7 min read
Two ways of counting the same trialswritten down by investigators0.12%malnutrition, reportedfound in placebo bloodwork1.77%lymphocytes under 910found in active-arm bloodwork2.9%lymphocytes under 910A low lymphocyte count is a marker, not a diagnosis. Both arms had some.

Two numbers describe the same trials. One came from a doctor writing something down. The other came from a blood test.

They do not agree, and the gap is the point. [1]

What each number counts

Investigators recorded malnutrition as an adverse event in 0.12% of participants. That is about one person in eight hundred. Anything logged that way has to be felt, mentioned and then written down, which is the same three-step filter that sits behind a coded side effect.

The lab screening tells a different story. Total lymphocyte counts below 910 per microliter turned up in 2.90% of people on active therapy. On placebo it was 1.77%.

Print both placebo and active or the comparison lies. The excess on the drug is roughly one percentage point, not the whole 2.90. Low lymphocytes happen without any drug at all.

How big the deficit is

Daily energy intake fell between 24.0% and 39.2%, depending on the drug. The authors model daily deficits reaching 1,200 kcal.

That figure is estimated, not measured. Still, a deficit near that size is the mechanism these drugs work by, and it is also the reason nutrition is a question at all. You cannot eat a third less and keep the same amount of everything else.

The fat-free mass number

Tirzepatide at 15 mg lost 1.60 kg of fat-free mass, which the authors put at 2.80% of body weight. That is one drug at one dose.

It sits inside the wider question of how much of the loss is muscle, and the answer keeps depending on what you compare it against.

What the authors want done

They propose a stepped algorithm: albumin and lymphocyte count at baseline, repeated at weeks 12, 24 and 52, with defined thresholds for acting.

That is a proposal in a paper. No guideline body has adopted it, and nothing here is a reason to demand a blood panel from a telehealth form. It is a reason to know that the question exists, especially past 65, and to raise it with whoever prescribes.

What it costs to check

Bloodwork is cheap next to the drug. Most sellers do not include it.

So monitoring is a line nobody quotes you, which is the same shape as the cost of keeping the muscle — real, avoidable, and absent from every price page on the internet.

Frequently asked

Do GLP-1 drugs cause malnutrition?
Investigators recorded it in 0.12% of trial participants. Blood screening flagged low lymphocyte counts in 2.90% on active therapy against 1.77% on placebo, so the excess is about one percentage point.
Is a low lymphocyte count the same as being malnourished?
No. It is a marker that tracks with poor nutrition, and infections, stress and ordinary variation move it too.
How much does eating drop?
Daily energy intake fell 24.0% to 39.2% across drug classes, with model-estimated daily deficits reaching 1,200 kcal. That estimate comes from a model rather than measured intake.
Should I get blood tests?
The authors propose albumin and lymphocyte screening at baseline and at weeks 12, 24 and 52, particularly past 65. No guideline body has adopted that; it is a question for whoever prescribes.

Sources

  1. [1] Ampofo E, et al. (2026). A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy Obesity Science & Practice. PMID 42707648

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk

More in Evidence